SEC Form 4
Tango Therapeutics, Inc. (TNGX) insider trading
In the 12 months to Oct 26, 2026, 3 TNGX insiders reported open-market sales of $11.8M across 13 filings; no open-market purchases were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $11.8M
- 13 filings · 3 insiders
- Open-market purchases
- $0
- 0 filings
- Pre-arranged sales (10b5-1)
- 12 of 13
- $7.0M of $11.8M sold (59%)
Who traded TNGX, and when
- Sale
- Sale, pre-arranged (10b5-1)
TNGX daily close from Oct 27, 2025 to Oct 26, 2026, between $7.51 and $32.90, last $22.46. 13 sale and 0 purchase filings by 3 insiders, marked at their filing dates. Adam Crystal, President, R&D: sold $6.8M across 11 filings, first filed Feb 27, 2026, last Oct 5, 2026. Third Rock Ventures IV, L.P., 10% owner: sold $4.8M across 1 filing, first filed Oct 27, 2025, last Oct 27, 2025. Jessica Newcomb, Principal Accounting Officer: sold $198.6K across 1 filing, first filed Sep 24, 2026, last Sep 24, 2026.
Largest mark · tap a row for others
Third Rock Ventures IV, L.P. · 10% owner
Sale $4,846,575
477,401 shares at $10.15 avg
Filed Oct 27, 2025 · traded Oct 23
Close on filing date $7.77
Adam Crystal · President, R&D
President, R&D
$6.8M soldThird Rock Ventures IV, L.P. · 10% owner
10% owner
$4.8M soldJessica Newcomb · Principal Accounting Officer
Principal Accounting Officer
$198.6K soldOpen-market trades
13 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Adam Crystal | President, R&D | $6.8M | — | 11 | 100% of sales | |
| Third Rock Ventures IV, L.P. | 10% owner | $4.8M | — | 1 | — | |
| Jessica Newcomb | Principal Accounting Officer | $198.6K | — | 1 | 100% of sales |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Adam Crystal President, R&D | SalePre-arranged (10b5-1) | 27,000 | $24.47 | $660.8K | 116,343 | |
traded | Jessica Newcomb Principal Accounting Officer | SalePre-arranged (10b5-1) | 8,200 | $24.22 | $198.6K | 61,521 | |
traded | Adam Crystal President, R&D | SalePre-arranged (10b5-1) | 27,000 | $22.37 | $603.9K | 115,743 | |
traded | Adam Crystal President, R&D | SalePre-arranged (10b5-1) | 27,000 | $27.24 | $735.5K | 137,476 | |
traded | Adam Crystal President, R&D | SalePre-arranged (10b5-1) | 27,000 | $29.59 | $798.9K | 123,114 | |
traded | Adam Crystal President, R&D | SalePre-arranged (10b5-1) | 27,000 | $22.87 | $617.6K | 115,743 | |
traded | Adam Crystal President, R&D | SalePre-arranged (10b5-1) | 27,000 | $21.23 | $573.1K | 116,843 | |
traded | Adam Crystal President, R&D | SalePre-arranged (10b5-1) | 38,460 | $25.00 | $961.5K | 112,622 | |
traded | Adam Crystal President, R&D | SalePre-arranged (10b5-1) | 27,000 | $21.20 | $572.5K | 112,622 | |
traded | Adam Crystal President, R&D | SalePre-arranged (10b5-1) | 12,000 | $20.11 | $241.3K | 112,622 | |
traded | Adam Crystal President, R&D | SalePre-arranged (10b5-1) | 20,251 | $15.00 | $303.8K | 112,622 | |
traded | Adam Crystal President, R&D | SalePre-arranged (10b5-1) | 54,345 | $12.77 | $694.2K | 132,873 | |
traded | Third Rock Ventures IV, L.P. 10% owner | Sale | 477,401 | $10.15 | $4.8M | 13,386,574 |
GET /stocks/filings/vX/form-4?tickers=TNGX&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"TNGX"
],
"issuer_cik": "0001819133",
"owner_cik": "0001825445",
"accession_number": "0001193125-26-414500",
"form_type": "4",
"filing_date": "2026-10-05",
"period_of_report": "2026-10-01",
"issuer_name": "Tango Therapeutics, Inc.",
"issuer_trading_symbol": "TNGX",
"owner_name": "Crystal Adam",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "President, R&D",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-10-01",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 600,
"transaction_price_per_share": 25.32,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 115743,
"transaction_value": 15192,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."
},
{
"id": "F3",
"description": "Represents the weighted average sales price per share. The shares sold at prices ranging from $25.04 to $25.41 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."
}
]
},
{
"tickers": [
"TNGX"
],
"issuer_cik": "0001819133",
"owner_cik": "0001825445",
"accession_number": "0001193125-26-414500",
"form_type": "4",
"filing_date": "2026-10-05",
"period_of_report": "2026-10-01",
"issuer_name": "Tango Therapeutics, Inc.",
"issuer_trading_symbol": "TNGX",
"owner_name": "Crystal Adam",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "President, R&D",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-10-01",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 26400,
"transaction_price_per_share": 24.4547,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 116343,
"transaction_value": 645604.08,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."
},
{
"id": "F2",
"description": "Represents the weighted average sales price per share. The shares sold at prices ranging from $23.96 to $24.95 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 27 records
- Option exercises9 records
- Tax withholding (sold to cover)6 records
- Grants and awards12 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
- Counted once
- When several owners (a fund and its partners, say) report the same trade, it's counted once. Corrected filings replace the originals.
Frequently asked questions
Has Tango Therapeutics, Inc.'s CEO sold stock?
No. Malte Peters (CEO) made no open-market sales filed as CEO in the last 12 months.
How current is TNGX’s insider data?
These are TNGX Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track TNGX insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for TNGX every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.